HR0123LRB103 31336 LAW 58770 r


  
1
HOUSE RESOLUTION

  
 
2    WHEREAS, The members of the Illinois House of 
3Representatives wish to congratulate CSL Behring on the 
4occasion of operating its manufacturing facility in the 
5Kankakee region for 70 successful years; and
  
 
6    WHEREAS, CSL Behring's parent company, CSL, is a leading 
7global biotechnology company with a dynamic portfolio of 
8medicines that provide lifesaving products to patients in more 
9than 100 countries; and
  
 
10    WHEREAS, CSL Plasma, a CSL company, operates one of the 
11world's largest and most sophisticated plasma collection 
12networks throughout the United States; in Illinois, it 
13operates 15 centers that collect plasma used for the sole 
14purpose of manufacturing plasma-derived therapies; and
  
 
15    WHEREAS, CSL is opening its newest plasma collection 
16center on the south campus of its Kankakee manufacturing site, 
17thereby continuing to build on its presence in the Kankakee 
18region; and
  
 
19    WHEREAS, CSL, a global biotech leader that discovers, 
20develops, and delivers innovative therapies so patients can 
21live their lives to the fullest, has recently launched 
 
 
HR0123- 2 -LRB103 31336 LAW 58770 r

1HEMGENIX®, the first and only gene therapy treatment to treat 
2severe Hemophilia B; therefore, be it
  
 
3    RESOLVED, BY THE HOUSE OF REPRESENTATIVES OF THE ONE 
4HUNDRED THIRD GENERAL ASSEMBLY OF THE STATE OF ILLINOIS, that 
5we congratulate CSL Behring for its 70 years in the Kankakee 
6region and throughout the State of Illinois, addressing unmet 
7medical needs and helping patients around the world live full 
8lives; and be it further
  
 
9    RESOLVED, That a suitable copy of this resolution be 
10presented to CSL Behring as an expression of our esteem and 
11respect.